We enable the acceleration of life science research
and development in the pursuit of improved human health
Global Response Aid (GRA)
At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.
Agility became a shareholder alongside Cellvera in Global Response Aid (GRA) to develop innovative solutions to the challenges posed by the COVID-19 pandemic and beyond.
GRA is as a permanent platform for solution to public health care challenges that seeks to bridge the gaps between disparate stakeholders within the global public health ecosystem including but not limited to pharmaceutical companies, medical device manufacturers, end users, governments, regulators, epidemiological researchers, and technology providers.